Cancer drug trial success

Scientists have developed new therapeutic approaches to cancer. The drug trial (APR-246) aimed to test the effects of a novel compound on a specific protein, p53, found to be mutated in over 50% of all cancers. The p53 gene is from a class of genes called tumor suppressors which are mutated in all cases of one form of ovarian cancer (high grade serous), but have proved difficult to target in the past.